Kidney Cancer Research Summit (KCRS21)
We continue to collaborate, share innovations, and discuss research progress at our annual summit.
KCRS21
October 7-8, 2021
KCRS21 consisted of an in-person meeting in Philadelphia, Pennsylvania and also a hybrid format that included a concurrent interactive program broadcast online via Zoom webinar.
KCRS is an annual meeting held in October which focuses on basic, translational, and clinical kidney cancer research. This meeting is fueled by the ideas and research funded through the Department of Defense CDMRP-KCRP awards.
The goal for KCRS is to present the important, innovative research funded by the KCRP. We also aim to connect researchers from around the world to share their work.
This years dynamic, interactive meeting focused on the latest basic science, translational, and clinical research in kidney cancer.
Recap of KCRS21
Countries from across the globe
Registrants for event
U.S. States represented
KidneyCAN is proud to have held the 3rd annual Kidney Cancer Research Summit, a meeting focused on basic and translational science, as well as cutting edge translational research, in October 2021.
This work is fueled by the funding from the Department of Defense CDMRP – KCRP.
It’s one of the most exciting things I’ve ever participated in. We’re bringing together clinicians, physician scientists, and bench scientists to talk about kidney cancer research. The goal is to invigorate the science and spur breakthroughs.
Dr. Hans Hammers, UTSW
Join Our Grassroots Army
Join Us!
Join this free symposium to understand how your quality of life and symptom management during #kidneycancer treatment can be improved by support from palliative care specialists.
This event is provided by our friends at the Judy Nicholson Kidney Cancer Foundation. Register here: https://jnfkidneycancer.org/supporting-patients-family-the-role-of-palliative-care/
Does #kidneycancer run in my family?
What do my genes tell me about kidney cancer?
On October 1st, Dr. Nathanson will break down risks of kidney cancer that runs in families in language we can all understand. She will present the very latest research in the field of kidney cancer genetics, offering information to share with family members and inform decision-making.
More information and registration at: https://www.med.upenn.edu/kidney2021/
Today’s science may lead to breakthrough treatments for a life-threatening condition that affects millions. To deliver on that promise, we need sustained, robust funding for the National Institutes of Health.
Today, KidneyCAN joins Rally for Medical Research to ask #Congress to fund the NIH.
Here's why:
• Medical research funded through the NIH, the largest source of funding for medical research in the world, has been a driving force behind many decades of advances that have improved the health of people in every corner of America.
• Thanks in large part to NIH-funded research, Americans are living longer, healthier lives and advances that were once unimaginable, such as sequencing the human genome, have been achieved and have opened a world of unprecedented opportunities for science, medicine and health.
• NIH funding contributed to every one of the 210 new drugs approved by the Food and Drug Administration (FDA) between 2010 and 2016, including 84 first-in-class products to treat a wide range of diseases.
• Investment in medical research can limit future costs of care. The vast majority of our health care dollars are spent on treating chronic diseases that could be managed more effectively with better therapies or, in some cases, prevented. We can meet these challenges head-on, but in order to do so, medical research must be a strong national priority.
#RallyMedRes #FundNIH
Did you know? September 21 is #TakeALovedOneToTheDoctor day!
Building a care team and getting support is a key piece of your cancer journey. Check out KidneyCAN's resources for patients and caregivers at https://kidneycan.org/build-a-care-team/
We just published our August newsletter, filled with exciting #kidneycancer research updates, news, and events. Don't miss a very special feature highlighting an inspiring member of our community.
Have a great weekend!
https://conta.cc/3sRMguh
REMINDER: Do you have questions about participating in clinical trials and how to find trials for you? Do you know the risks and benefits? We are hosting a special Facebook Live with a medical oncologist and clinical trial patient to answer all your questions live, including:
• What is a clinical trial?
• Where do I find clinical trials for kidney cancer?
• What are important questions to ask about a trial?
• What is informed consent?
• What are good clinical practices?
• What can patients expect during a trial?
• What are the risks and benefits of participating in a trial?
• What is the difference between participating at an academic institution versus a freestanding clinical research organization (CRO)?
Will you join us? RSVP now so you get a Facebook notification when we go live: https://fb.me/e/1JfopJa6J
🚨🚨 RESEARCH NEWS
Lenvantinib (by Eisai) + Keytruda (by Merck) is now
U.S. Food and Drug Administration approved for #kidneycancer. Wonderful to have this powerful new combo as a treatment option for patients with advanced #RCC!
Dr. Toni Choueiri of Dana-Farber Cancer Institute says, "This is another important combination option for advanced kidney cancer patients. The results in term of responses including complete responders are the highest to date, albeit with a bit different patient populations. The hope is to continue building on doublets, like pembro/Len with other active drugs, that are able to induce more deep and sustainable remissions."
Great news!
More information here: https://cancernetwork.com/view/pembrolizumab-lenvatinib-approved-by-the-fda-for-the-treatment-of-first-line-advanced-rcc
We lose almost 40 people per day to kidney cancer in the United States. The need for research funding is urgent.
For #DistrictDays, the #kidneycancer community is meeting with members of #Congress all over the United States to ask for robust funding of kidney cancer research.
We want Congress to
1. Maintain the $50 million currently allocated for KCRP for
Fiscal Year 2022.
2. Increase the NIH budget by $3.5 billion for Fiscal Year 2022.
3. Support the creation of ARPA-H (the Advanced Research
Projects Agency - Health) at NIH with an additional $3 billion.
4. Continue supporting legislative initiatives that contribute to
robust, sustainable funding for medical research.
5. Continue to incorporate the patient perspective on legislative policy matters.
Thank you to the many delegates from all over the country who are speaking on behalf of patients, caregivers, friends, and family members today. Thank you to doctors and researchers from the medical community who've made time today to lift their voices with ours.
Let's work together to #fundthecure.
#AcceleratingCures
Thank you to Senator Grassley's office for meeting with us today. Here, KidneyCAN President and #kidneycancer survivor Bryan Lewis, along with our friend and patient Shari, and Dr. Zakharia speak up about the need for robust research funding.
76,000+ will be diagnosed in 2021.
14,000 Americans will lose their lives to kidney cancer this year.
It's urgent! Let's #fundthecure.
#acceleratingcures #districtdays
Here we go!
#KidneyCancer advocates across the #USA are speaking with #onevoice today. We're asking #Congress to #fundthecure with robust research funding for the National Institutes of Health, the Congressionally Directed Medical Research Programs - Kidney Cancer Research Program, and ARPA-H, which will devote specific funding to cancer research initiatives.
We lose 40 people per day to kidney cancer. This is urgent. The time is NOW.
KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Programs (CDMRP) or KCRP (Kidney Cancer Research Program). Our work is funded by grassroots donors in the kidney cancer community.Â
